POINT Biopharma Global Inc. (NASDAQ: PNT) Sold to Eli Lilly and Company (NYSE: LLY)

Client Type: Public Company

We counseled POINT Biopharma Global Inc. (NASDAQ: PNT), a radiopharmaceutical company with a pipeline of clinical and preclinical-stage radioligand therapies in development for the treatment of cancer, in its sale to Eli Lilly and Company (NYSE: LLY), an American pharmaceutical company for approximately $1.4 billion.

We counseled POINT Biopharma Global Inc. (NASDAQ: PNT), a radiopharmaceutical company with a pipeline of clinical and preclinical-stage radioligand therapies in development for the treatment of cancer, in its sale to Eli Lilly and Company (NYSE: LLY), an American pharmaceutical company for approximately $1.4 billion.